159 related articles for article (PubMed ID: 31654608)
21. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
22. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
[TBL] [Abstract][Full Text] [Related]
23. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment.
Stasi C; Sadalla S; Carradori E; Monti M; Petraccia L; Madia F; Gragnani L; Zignego AL
Curr Med Res Opin; 2020 Feb; 36(2):245-249. PubMed ID: 31702411
[No Abstract] [Full Text] [Related]
25. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.
Benvegnù L; Gios M; Boccato S; Alberti A
Gut; 2004 May; 53(5):744-9. PubMed ID: 15082595
[TBL] [Abstract][Full Text] [Related]
26. The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study.
Ok KS; Jeong SH; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Bae SH; Lee HC
Medicine (Baltimore); 2016 Aug; 95(35):e4594. PubMed ID: 27583874
[TBL] [Abstract][Full Text] [Related]
27. [The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection].
Garbuzenko DV
Vopr Virusol; 2021 Nov; 66(5):331-339. PubMed ID: 34738448
[TBL] [Abstract][Full Text] [Related]
28. The future of liver transplantation for viral hepatitis.
Durand F; Francoz C
Liver Int; 2017 Jan; 37 Suppl 1():130-135. PubMed ID: 28052618
[TBL] [Abstract][Full Text] [Related]
29. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
30. Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis.
Jang JW; Choi JY; Kim YS; Yoo JJ; Woo HY; Choi SK; Jun CH; Lee CH; Sohn JH; Tak WY; Lee YR; Han KH
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1954-1963.e3. PubMed ID: 29753085
[TBL] [Abstract][Full Text] [Related]
31. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.
Cramp ME; Rosenberg WM; Ryder SD; Blach S; Parkes J
BMC Gastroenterol; 2014 Aug; 14():137. PubMed ID: 25100159
[TBL] [Abstract][Full Text] [Related]
32. NIH consensus development statement on management of hepatitis B.
Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
[TBL] [Abstract][Full Text] [Related]
33. Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver.
Aghemo A; Masarone M; Montagnese S; Petta S; Ponziani FR; Russo FP;
Dig Liver Dis; 2020 Sep; 52(9):937-941. PubMed ID: 32703730
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
[TBL] [Abstract][Full Text] [Related]
35. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
[TBL] [Abstract][Full Text] [Related]
36. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.
Ikeda K; Marusawa H; Osaki Y; Nakamura T; Kitajima N; Yamashita Y; Kudo M; Sato T; Chiba T
Ann Intern Med; 2007 May; 146(9):649-56. PubMed ID: 17470833
[TBL] [Abstract][Full Text] [Related]
37. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.
Fraňková S; Urbánek P; Husa P; Němeček V; Razavi H; Razavi-Shearer D; Chlíbek R; Šperl J
Cent Eur J Public Health; 2019 Jun; 27(2):93-98. PubMed ID: 31241282
[TBL] [Abstract][Full Text] [Related]
38. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
39. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
40. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort).
Gentile I; Scotto R; Coppola C; Staiano L; Amoruso DC; De Simone T; Portunato F; De Pascalis S; Martini S; Macera M; Viceconte G; Tosone G; Buonomo AR; Borgia G; Coppola N
Hepatol Int; 2019 Jan; 13(1):66-74. PubMed ID: 30523552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]